United Therapeutics Corporation (NASDAQ: UTHR) CEO Martine A. Rothblatt, on Wednesday, bought 13,649 shares of the company for $43.60 per share.
Rothblatt has purchased UTHR shares on 7 other occasions in the past year. The average price for these purchases has been $42.15 per share.
UTHR shares have fallen 3.32% so far this year, compared with a gain of 8.86% for the Nasdaq. In today’s trading, the stock rose 4.34% to $45.68 on above average volume of 911,779.
Based in Silver Spring, Maryland, United Therapeutics is a biotechnology company engaged in the development and commercialization of products to address unmet medical needs of patients with chronic and life-threatening conditions.
In its most recently reported quarter (Q1), UTHR posted total revenue of $204.2 million, compared with $162.5 million reported for the same period in the previous year. UTHR’s net income for the quarter was $70.8 million, or $1.32 per basic share, compared with $16.4 million, or $0.28 per basic share reported for the same period in the previous year.
Commenting on the first-quarter results, Rothblatt had said that he is pleased with UTHR’s first-quarter results and that this is an important stepping stone toward the company’s revenue guidance for 2012 and 2013.
For 2012, UTHR expects revenue to fall within a range of 5% above or below $875 million.
Recent Comments